Alzheimer's Clinical Trials

70 recruitingLast updated: June 18, 2026

There are 70 actively recruiting alzheimer's clinical trials across 40 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include Miami, Florida, United States, Orlando, Florida, United States, Tampa, Florida, United States. Updated daily from ClinicalTrials.gov.


Alzheimer's Trials at a Glance

70 actively recruiting trials for alzheimer's are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Not Applicable with 26 trials, with the heaviest enrollment activity in Miami, Orlando, and Tampa. Lead sponsors running alzheimer's studies include Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Anhui Medical University, and AC Immune SA.

Browse alzheimer's trials by phase

Treatments under study

About Alzheimer's Clinical Trials

Looking for clinical trials for Alzheimer's? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alzheimer's trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alzheimer's clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 70 trials

Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled428 locationsNCT05980949
Recruiting
Early Phase 1

Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

DementiaAlzheimer DiseaseProgressive Aphasia+3 more
University of Texas at Austin120 enrolled1 locationNCT06511752
Recruiting
Not Applicable

Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment

FTDAD - Alzheimer's DiseaseAD-MCI+1 more
Tianjin Huanhu Hospital60 enrolled1 locationNCT07643363
Recruiting
Phase 2

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Mild, Moderate, or Severe Alzheimer's Disease
Elixiron Immunotherapeutics Inc.15 enrolled2 locationsNCT06745583
Recruiting

InRAD Observational Study

Mild Cognitive Impairment (MCI)Alzheimer's Disease(AD)Subjective Cognitive Decline (SCD)+1 more
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation50,000 enrolled2 locationsNCT07213700
Recruiting
Phase 2Phase 3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled49 locationsNCT07284472
Recruiting
Phase 1Phase 2

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Alzheimer s DiseaseBeta-AmyloidProdromal Alzheimer's Disease+2 more
AC Immune SA304 enrolled26 locationsNCT05462106
Recruiting
Phase 2

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

Mild Cognitive ImpairmentEarly Alzheimer's DiseaseAD-MCI
Bernard (Barry) Baumel10 enrolled1 locationNCT07512362
Recruiting
Phase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled78 locationsNCT07033494
Recruiting
Phase 1Phase 2

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

Mild to moderate Alzheimer's disease
Xuanwu Hospital, Beijing33 enrolled1 locationNCT07457125
Recruiting
Phase 2

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

Alzheimer s DiseaseMild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Weill Medical College of Cornell University20 enrolled1 locationNCT07553338
Recruiting
Phase 4

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

Alzheimer Dementia (AD)Alzheimer s DiseaseMCI-AD, Early Stage Alzheimer's Disease
First Affiliated Hospital of Wenzhou Medical University200 enrolled1 locationNCT07604896
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled40 locationsNCT06887192
Recruiting
Phase 1

A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy

MCIAD - Alzheimer's Disease
Eli Radiopharma18 enrolled1 locationNCT07580703
Recruiting
Phase 2

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia
Ono Pharmaceutical Co., Ltd.90 enrolled38 locationsNCT06803823
Recruiting
Not Applicable

Mindfulness to Enhance Cognitive Health in Latino Older Adults

MindfulnessAlzheimer's Disease Related Dementia
Washington University School of Medicine60 enrolled1 locationNCT07040904
Recruiting
Not Applicable

Adapting RDAD for DS

Down Syndrome (DS)Alzheimer's Disease(AD)
University of Kansas Medical Center40 enrolled1 locationNCT07425769
Recruiting
Not Applicable

Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes

DementiaDiabetesHypoglycemia+1 more
Indiana University62 enrolled1 locationNCT05643144